Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

One of Pfizer’s Duchenne gene therapy trials put on hold in wake of patient death as high-dose AAV concerns still cloud field

4 years ago

Roche's Spark invests $575M for new gene therapy center in central Philadelphia as part of Drexel partnership

4 years ago

Pfizer opens doors at newest gene therapy site in NC as part of $800M push into next-gen drugs

4 years ago

IN8bio's 'off-the-shelf' gamma delta T cells stave off relapse for high-risk leukemia patients in very early data cut

4 years ago

Hopes for non-viral gene therapy take a blow as Generation Bio announces significant setback

4 years ago

#ASH21: The Jay Bradner interview: 'We're working up a goodly number of deals'

4 years ago

Could the next gene therapy manufacturing hub be Cincinnati? A $100M bet says yes

4 years ago

ASH: Sanofi uncorks late-stage data for RNAi drug fitusiran in hemophilia, with all eyes on safety profile

4 years ago

Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

4 years ago

ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients

4 years ago

ASH: After a pilot study offers a glimpse of hope for Tessa's CD30-targeting CAR-T, execs sprint toward a pivotal trial

4 years ago

ASH: Novartis rolls out early data for a pair of 'second-gen' CAR-Ts with more productive cells delivered faster

4 years ago

ASH: Gilead's CAR-T Yescarta holds up in more first-line lymphoma patients as part of earlier use push

4 years ago

ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field

4 years ago

ASH: Tessa Therapeutics' next-gen cell therapy clears four patients' tumors in early study

4 years ago

ASH: Gilead's Kite unveils more data on Yescarta's win in second-line lymphoma patients, setting up battle for SOC

4 years ago

ASH: With Yescarta leading in earlier-line lymphoma, Bristol Myers keeps the heat on with full data for Breyanzi

4 years ago

Ever optimistic despite concerns, BrainStorm teams with Catalent to prep for possible approval for ALS drug

4 years ago

Taipei's Bora wants in on the CDMO game as report shows plenty of room for industry growth

4 years ago

With new pivotal data, uniQure and CSL Behring dash to the FDA with a potential blockbuster gene therapy for hemophilia B

4 years ago

Fledgling Stanford spinout promising 3D models of fully human tissue wins the backing of some big-time investors

4 years ago

'We're in': Roche and Genentech join forces on a multibillion-dollar discovery pact with a brash AI upstart

4 years ago

Apple Tree Partners leaps across the pond to launch a UK biotech looking to crack the secrets of dendritic cells

4 years ago

Adicet unveils early responses for off-the-shelf drug leveraging rare T cells. Will durability hold up?

4 years ago

First page Previous page 33 34 353637 38 39 Next page Last page